Will rapamycin overtake metformin as a Longevity therapy?

Latest articles

“World’s first” cultural-matching app for care sector launches

Care receivers can be paired with carer based on religious understanding and culture thanks to AI tech developed during pandemic. A graduate has created what...

Biotech LyGenesis expands its liver regeneration tech

A new peer-reviewed paper demonstrates the success of using fat-associated lymphoid clusters as expandable niches for ectopic liver regeneration. LyGenesis, a clinical-stage biotech developing cell...

NURO embarks on funding round for neurotech communication system

World’s first multimodal neurotech operating system from NURO allows you to communicate using just your brain. DISCLOSURE: Longevity.Technology (a brand of First Longevity Limited) has...

It’s time to reboot longevity and healthy aging

Dr Michael Roizen calls for fundamental societal changes to ensure the benefits of longevity and healthy aging are realised. Later this year, best-selling author Michael...

Most read

New supplement slows aging and promotes weight loss

Sugar-proof your way to a longer life. Reducing AGEs to slow aging and increase weight loss – how one supplement is fighting the war...

An antiaging supplement that also reduces appetite?

One for the AGEs: Juvify signs IP licensing deal with Buck Institute for GLYLO antiaging supplement that aims to reduce glycation. A researcher at the...

Resveratrol – the small molecule with big antiaging ideas

When it comes to antiaging molecules, we can learn a thing or two from plants. As so often in natural world, plants have a few...

Editor's picks

“World’s first” cultural-matching app for care sector launches

Care receivers can be paired with carer based on religious understanding and culture thanks to AI tech developed during pandemic. A graduate has created what...

Biotech LyGenesis expands its liver regeneration tech

A new peer-reviewed paper demonstrates the success of using fat-associated lymphoid clusters as expandable niches for ectopic liver regeneration. LyGenesis, a clinical-stage biotech developing cell...

NURO embarks on funding round for neurotech communication system

World’s first multimodal neurotech operating system from NURO allows you to communicate using just your brain. DISCLOSURE: Longevity.Technology (a brand of First Longevity Limited) has...

Click the globe for translations.

Animal and human trials progress development of rapamycin as an anti-aging therapy.

The development of drugs to counteract the aging process is rapidly evolving and has led to the identification of numerous potential compounds, which are currently under investigation. Although several health supplements claim to extend lifespan and healthspan, their efficacy lacks scientific evidence from comprehensive and well-designed preclinical and human studies.

The line between supplement and therapy is quite thin sometimes, but the two favourites remain rapamycin and metformin.

Longevity.Technology: In a recent study, scientists investigated the effects of the bacterial metabolite rapamycin on the mouse lifespan and identified that late‐life rapamycin treatment extended mouse lifespan in a sex-specific manner. This study was a collaborative effort between scientists at the Barshop Institute for Longevity and Aging Studies (University of Texas Health Science Center, USA), the Department of Pathology and Geriatrics Center, University of Michigan (USA), the Medical Research Council Mitochondrial Biology Unit (University of Cambridge, UK) and The Jackson Laboratory (USA). The findings of the study were published in November 2020 in the journal Aging Cell [1].

To systematically evaluate the ability of rapamycin to extend lifespan, scientists treated middle-aged mice with three different dosing regimens. When treatment was initiated at 20 months (the equivalent of 56–69 years in humans), rapamycin significantly prolonged the survival of mice regardless of the sex [1, 2]. Interestingly, prolonged rapamycin treatment (three months) extended the lifespan of male but not of female mice.

Scientists confirmed the Longevity-promoting effects of intermittent rapamycin regimens, wherein rapamycin was administered at one-month intervals interspersed with drug-free months; however, continuous exposure to rapamycin was more effective in female mice than intermittent rapamycin regimens [1].

The researchers also tested the potential Longevity-promoting effects of minocycline, β‐guanidinopropionic acid and MitoQ, among others, all of which have been previously shown to mitigate factors driving aging. Nevertheless, none of these drugs altered mouse survival in either sex, further highlighting the ability of rapamycin to extend lifespan. Yep, we understand that translation from mice to human studies is the next challenge.

 


 

Scientists confirmed the Longevity-promoting effects of intermittent rapamycin regimens, wherein rapamycin was administered for 1-month intervals interspersed with drug-free months

 


 

Though encouraging, the findings of this study should be interpreted with caution, since the authors of the study noted differences in the weight gain of mice during the rapamycin treatment.

The ability of rapamycin to prolong survival has been previously shown in fruit flies, where rapamycin extended lifespan by promoting cell survival under stressful conditions. The life-extending effects of rapamycin alone or in combination with metformin – the first-line treatment for type-2 diabetes – have also been demonstrated in mice, although variations in study design and treatment regimens hinder scientists’ ability to draw conclusions [3].

AgelessRX, a new company dedicated to developing scientifically proven interventions to prevent and treat age-related diseases, is set to launch the Participatory Evaluation of Aging with Rapamycin for Longevity (PEARL) trial in collaboration with the University of California to systematically investigate the efficacy and safety of rapamycin use to promote Longevity. The study will involve over 1,000 adults aged 50 years or older who will receive rapamycin for up to a year [4].

Even though rapamycin is FDA-approved for use in transplant recipients to prevent organ rejection, a rapamycin dosing consensus needs to be established to maximise its anti-aging effects. PEARL and other well-designed large-cohort controlled studies are expected to provide clinical evidence of the rapamycin’s ability to extend life, as well as identify the potential side effects of life-long rapamycin use.

[1] https://onlinelibrary.wiley.com/doi/full/10.1111/acel.13269

[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3733029/

[3] https://link.springer.com/article/10.1007/s11357-020-00274-1

[4] https://www.agelessrx.com/pearl

Image credit: Ricky Kharawala / Unsplash

Christos Evangelou
Since the completion of his undergraduate and doctoral studies in Molecular Biosciences, Christos has been working in the medical communications industry, driven by his passion for communicating sciences. Apart from helping researchers to publish their studies, Christos writes articles related to sciences and medicine.

Most popular

New supplement slows aging and promotes weight loss

Sugar-proof your way to a longer life. Reducing AGEs to slow aging and increase weight loss – how one supplement is fighting the war...

An antiaging supplement that also reduces appetite?

One for the AGEs: Juvify signs IP licensing deal with Buck Institute for GLYLO antiaging supplement that aims to reduce glycation. A researcher at the...

Resveratrol – the small molecule with big antiaging ideas

When it comes to antiaging molecules, we can learn a thing or two from plants. As so often in natural world, plants have a few...

Sugar-proof your health with the GLYLO weight loss and antiaging supplement

Move your New Year's resolution up a gear with GLYLO, a double-action supplement that can increase weight loss while also slowing aging. Choosing an effective...

Related articles

Biotech LyGenesis expands its liver regeneration tech

A new peer-reviewed paper demonstrates the success of using fat-associated lymphoid clusters as expandable niches for ectopic liver regeneration. LyGenesis, a clinical-stage biotech developing cell...

Mental illness drug discovery company Neurai Life Sciences launches

AI will drive discovery of innovative small molecules and next generation therapies to treat mental health disorders. Wuhan, a bioceutical company focused on alternative plant-based...

StarkAge secures 2 million euros for senescence targeting therapy

Funding from Bpifrance's Deeptech program will drive development of company’s immunotherapy approach targeting cellular senescence in age-related disease. French biotech startup StarkAge Therapeutics today announced...

Genflow IPO “starts a new chapter” for longevity biotech

Company floats on London Stock Exchange and becomes Europe’s first publicly traded longevity biotech. Today, Genflow Biosciences became the first longevity biotech IPO of 2022...

Roll up, roll up… it’s the Longevity Biotech Virtual Job Fair!

Amplifying the longevity biotech space with exciting opportunities and brand-new start. The new year brings new opportunities, and the new Longevity Biotech Virtual Job Fair...

    Subscribe to our newsletter